Madecassic Acid: From Korean Skincare Staple to a Promising Weapon Against Antibiotic-Resistant Bacteria

Table of Contents

1. Key Highlights:
2. Introduction
3. From a skincare ingredient to an antimicrobial lead
4. How madecassic acid interferes with bacterial respiration
5. Laboratory findings: extraction, modifications, and potency
6. Why cytochrome bd is an attractive antibiotic target
7. Centella asiatica: a medicinal plant with modern relevance
8. Computational screening: narrowing the field efficiently
9. From hit to medicine: the path forward and the major hurdles
10. Potential clinical roles and strategic deployment
11. Implications for skincare and the skin microbiome
12. Real-world precedents: how plant-derived drugs scaled into therapies
13. Resistance risk and mitigation strategies
14. Practical next steps: what researchers and funders should prioritize
15. Broader public-health context: new targets matter
16. Ethical, environmental, and supply considerations
17. What the discovery does and does not show today
18. Final considerations for clinicians, scientists, and policymakers
19. FAQ

Key Highlights:

• Researchers at the University of Kent and UCL identified madecassic acid, a compound from Centella asiatica, as an inhibitor of the bacterial cytochrome bd complex, blocking growth of antibiotic-resistant E. coli.
• Modified derivatives of the molecule increased potency; one derivative proved bactericidal at higher concentrations. The finding points to a new class of targets absent in humans, but substantial preclinical and clinical work remains.

Introduction

A molecule familiar to beauty shoppers for its role in so-called “Cica” creams has surfaced in laboratory tests as a candidate for a very different purpose: fighting antibiotic-resistant bacteria. Madecassic acid, extracted from Centella asiatica, demonstrated activity against antibiotic-resistant strains of E. coli by binding to a bacterial respiratory protein that humans do not possess. The discovery emerged from a collaboration between the University of Kent and University College London, combining computational screening with biochemical and microbiological assays, and was reported in RSC Medicinal Chemistry.

Antimicrobial resistance (AMR) already shapes clinical decision-making and public health planning. Projections that drug-resistant infections could cause tens of millions of deaths over the coming decades underscore the urgency of finding new mechanisms to neutralize pathogens. The madecassic acid work highlights a route that departs from traditional antibiotics that target cell wall synthesis, protein production, or DNA replication. It instead targets bacterial energy metabolism—specifically the cytochrome bd complex—opening an avenue that could yield narrow-spectrum agents with less off-target risk to human cells.

This article explains what the researchers found, why cytochrome bd matters, how plant-derived compounds have succeeded as therapeutics historically, what the path from discovery to medicine entails, and what the practical implications are for both infectious disease management and skincare formulations.

From a skincare ingredient to an antimicrobial lead

Centella asiatica, often called gotu kola, has a long ethnobotanical history across Asia. Contemporary cosmetic formulations frequently list ingredients such as madecassoside, asiaticoside, asiatic acid, and madecassic acid among “cica” or skin-repairing actives. Consumers encounter these names on serums and creams marketed for soothing, hydrating, or helping skin barrier function.

Laboratory science often takes cues from traditional uses. Researchers screened constituents of Centella asiatica with computational chemistry tools to identify molecules likely to bind bacterial proteins of interest. Madecassic acid emerged as a promising hit. Subsequent laboratory work validated the computational prediction: madecassic acid disrupts the function of the cytochrome bd complex in bacteria and suppressed growth of antibiotic-resistant Escherichia coli strains.

The transition from a cosmetic compound to an antibiotic lead illustrates how compounds with acceptable topical safety profiles can prompt deeper pharmacological investigations. The extraction of madecassic acid from a Vietnamese plant sample, followed by chemical modifications to improve activity, represents a common sequence in early drug discovery: identify a natural product, confirm biological activity, and begin structure-activity studies to optimize efficacy and drug-like properties.

How madecassic acid interferes with bacterial respiration

Bacterial survival within a host often requires metabolic flexibility. When exposed to host defenses, low oxygen niches, or immune-generated stressors such as nitric oxide, many bacteria rely on alternative respiratory complexes to maintain energy production and redox balance. The cytochrome bd complex is a terminal oxidase found in many Gram-negative bacteria and some Gram-positives that enables respiration under microaerobic or stressful conditions.

Madecassic acid binds to the cytochrome bd complex and impairs its function. Laboratory assays showed that exposure to madecassic acid halted the respiration-supported growth of antibiotic-resistant E. coli. Because cytochrome bd has no human or animal homolog, inhibitors that target it promise selectivity: they can suppress bacterial respiration without directly interfering with host mitochondrial function.

Targeting bacterial respiration differs fundamentally from many classical antibiotics. Rather than blocking synthesis of essential macromolecules or compromising cell wall integrity directly, cytochrome bd inhibitors undermine the energetic processes bacteria need to persist in hostile environments. This approach may be especially useful against pathogens dwelling in low-oxygen microenvironments such as abscesses, biofilms, or within certain host cells.

The mechanism also suggests potential synergy with other antibiotics. By impairing bacterial energy production and stress resilience, cytochrome bd inhibition could sensitize bacteria to drugs whose efficacy depends on active metabolic processes or exacerbate effects of immune-mediated killing.

Laboratory findings: extraction, modifications, and potency

The team extracted madecassic acid from a Centella asiatica sample collected in Vietnam. Initial in vitro bacteriological assays demonstrated that the native molecule binds cytochrome bd and impedes growth of resistant E. coli. With a validated target and measurable activity, researchers synthesized three modified derivatives to explore structure-activity relationships—that is, how changes to the chemical structure influenced binding, potency, and bactericidal behavior.

All three modified compounds retained the ability to block cytochrome bd and stop bacterial growth. One derivative showed bactericidal effects at higher concentrations, meaning it could kill the bacterial cells rather than merely inhibiting replication. This distinction—bacteriostatic versus bactericidal—is important in treating infections where eradication, rather than suppression, is preferred, such as in immunocompromised patients.

The combination of computer modeling and laboratory confirmation accelerated the prioritization of derivatives for synthesis. Computational docking identified potential modes of interaction between madecassic acid and the cytochrome bd complex, guiding chemists to modify positions on the molecule that might enhance binding affinity or improve other pharmacological properties.

Laboratory testing likely included standard antimicrobial assays—minimum inhibitory concentration (MIC) determinations to measure growth inhibition, time-kill assays to gauge bactericidal activity over time, and biochemical assays to confirm binding to cytochrome bd. Subsequent work will need to extend to cytotoxicity testing in mammalian cells, metabolic stability assays, and evaluation of in vivo efficacy in animal infection models.

Why cytochrome bd is an attractive antibiotic target

Several features make cytochrome bd an appealing target when compared with traditional antibiotic targets:

• Selectivity: Cytochrome bd is absent from human mitochondria and from animals, minimizing the risk of direct host toxicity from inhibitors that are reasonably specific.
• Role in persistence: The complex enables bacteria to respire under oxygen-limited conditions, contributing to survival in biofilms, within macrophages, or inside tissues where oxygen diffusion is limited.
• Stress tolerance: Cytochrome bd contributes to bacterial resistance against reactive nitrogen species such as nitric oxide and some oxidative stresses produced by host immune responses. Inhibiting it undermines bacterial defenses that are crucial during infection.
• Conserved presence among pathogens: Many clinically relevant Gram-negative pathogens—E. coli, Klebsiella, and certain strains of Pseudomonas—express cytochrome bd, making it a target across multiple species.

Historically, drug developers have been wary of targeting bacterial respiration because of concerns about host toxicity. The absence of cytochrome bd in humans changes that calculus. Additionally, targeting processes that are essential for survival during infection—rather than during routine growth in nutrient-rich lab media—may reduce selective pressure for rapid resistance development, though that remains to be determined empirically.

However, promising targets come with caveats. Bacteria possess redundant respiratory pathways; inhibition of a single oxidase may be bypassed by upregulation of alternate systems under some conditions. Understanding how bacteria respond to cytochrome bd inhibition—whether they compensate or whether the inhibition creates vulnerabilities that other drugs can exploit—is a major research priority.

Centella asiatica: a medicinal plant with modern relevance

Centella asiatica occupies a dual identity: centuries-old herbal remedy and contemporary cosmetic ingredient. Traditional uses span wound healing, anti-inflammatory applications, and cognitive-support claims in different cultural contexts. Modern phytochemistry has identified a suite of triterpenoid saponins and related molecules—asiaticoside, madecassoside, asiatic acid, and madecassic acid among them—that likely mediate many of these effects.

Skincare formulations advertise Centella extracts for their purported capacity to soothe irritated skin, support barrier repair, and reduce redness. Clinical and preclinical studies have explored the anti-inflammatory and collagen-stimulating effects of specific Centella components, providing partial mechanistic explanations for traditional claims.

The discovery that one of these components might inhibit bacterial respiration bridges traditional knowledge and modern pharmacology. The trajectory—from ethnobotanical observation to modern drug discovery—has precedent. Artemisinin, isolated from Artemisia annua and developed into the cornerstone of modern antimalarial therapy, transformed global health by converting a folk remedy into rigorously tested therapeutics. Paclitaxel, sourced from the Pacific yew tree, became a major anticancer drug after extensive chemical modification and synthetic production strategies. These examples illustrate how plant-derived compounds can yield lifesaving medicines when integrated with modern chemistry and pharmacology.

The Centella story differs in scale and complexity, but the principle is identical: a bioactive natural product offers a structural scaffold that medicinal chemists can refine into a therapeutic agent with appropriate potency, safety, and pharmacokinetics.

Computational screening: narrowing the field efficiently

The madecassic acid project combined computational screening with laboratory assays. Virtual screening and molecular docking predict how small molecules might interact with protein targets based on three-dimensional structures. Such in silico approaches help prioritize compounds for synthesis and experimental testing, reducing the time and material costs associated with screening large chemical libraries entirely by benchwork.

Docking to cytochrome bd requires an accurate structural model of the complex. Advances in cryo-electron microscopy, X-ray crystallography, and computational protein modeling have yielded structures or high-quality models for many bacterial respiratory complexes. With a model in hand, chemists and computational biologists can simulate binding poses, calculate approximate binding energies, and propose modifications likely to enhance interaction with key active-site residues.

Virtual screening is not definitive. False positives and negatives occur. Compounds predicted to bind well may fail in vitro because of solubility problems or steric hindrance within the living cell. Conversely, molecules with modest predicted binding may perform strongly in biological assays because of cell-permeation advantages or favorable metabolic stability. The Kent–UCL team validated computational predictions with biochemical and microbiological tests, following best-practice discovery pipelines.

The iterative loop—computational hypothesis, chemical synthesis, biological testing, and back to computational refinement—accelerates the optimization of natural-product scaffolds like madecassic acid.

From hit to medicine: the path forward and the major hurdles

A promising laboratory finding rarely turns into an approved drug without years of work and substantial investment. Moving madecassic acid or its derivatives from an experimental antibacterial to a licensed therapeutic requires overcoming scientific, technical, and commercial hurdles.

Key steps and challenges include:

• Lead optimization: Medicinal chemists must improve potency, selectivity, solubility, metabolic stability, and permeability. Natural products often possess bulky or polar groups that complicate absorption or lead to rapid metabolic clearance.
• Toxicology and safety: In vitro cytotoxicity testing lays groundwork, but systemic safety requires detailed animal toxicology studies, evaluation of genotoxicity, and assessment of off-target effects. Even targets absent in humans can yield toxic metabolites or provoke immune responses.
• Pharmacokinetics and delivery: For systemic infections, oral bioavailability or intravenous formulations must achieve therapeutic concentrations at infection sites. For localized infections or biofilms, topical, inhaled, or catheter-coating formulations might be viable.
• Spectrum of activity: Developers must determine whether the compound is narrow- or broad-spectrum. Narrow-spectrum agents can reduce collateral damage to the microbiome but may have limited market appeal. Broad-spectrum agents are commercially attractive but can drive resistance and microbiome disruption.
• Resistance evolution: Experiments should probe how easily bacteria develop resistance to cytochrome bd inhibitors and whether resistance mechanisms impose fitness costs or cross-resistance with existing drugs.
• Preclinical models: Efficacy must be demonstrated in animal infection models that replicate human disease conditions. These studies confirm therapeutic potential and guide dosing strategies.
• Regulatory pathway: Interacting with regulatory agencies early clarifies data requirements for human trials. For severe, unmet medical needs, accelerated pathways or “breakthrough” designations may be available, but they still require rigorous evidence of benefit and safety.
• Commercial incentives and manufacturing: Synthetic routes must be scalable and cost-effective. Developers must secure intellectual property or other incentives to justify the investment necessary for costly clinical trials.

These steps can take years and often fail at one of several stages. Yet the potential payoff—an antibiotic with a novel mechanism useful against resistant organisms—warrants substantial attention from public and private funders alike, given the global stakes posed by AMR.

Potential clinical roles and strategic deployment

If cytochrome bd inhibitors progress through development, their optimal clinical roles must be defined carefully. Several strategic uses are plausible:

• Adjunctive therapy: Combine cytochrome bd inhibitors with existing antibiotics to enhance killing of resistant strains or clear persistent infections. By disabling energy pathways, such inhibitors could sensitize bacteria to antibiotics that rely on active uptake or metabolic processes.
• Targeted therapy: Use in infections where bacteria rely heavily on cytochrome bd, such as biofilm-associated device infections, intracellular pathogens sheltered within phagocytes, or abscesses with low oxygen tension.
• Topical or localized use: For skin infections or wound care, formulations leveraging madecassic acid derivatives could combine antimicrobial action with other benefits derived from the Centella scaffold. Localized delivery can achieve high concentrations at the site of infection while minimizing systemic exposure.
• Antivirulence approach: Rather than outright killing, cytochrome bd inhibition could attenuate pathogen virulence, making infections more manageable for the host immune system and less likely to cause severe disease.

Clinical trials would need to evaluate these roles. Selection of endpoints—microbiological eradication, clinical improvement, reduction of hospitalization—will depend on the intended use and regulatory strategy.

Implications for skincare and the skin microbiome

Madecassic acid’s presence in topical skincare products raises questions about unintended antimicrobial effects on the skin microbiome. The skin hosts a diverse microbial ecosystem that contributes to barrier function, immune education, and protection against pathogens. Disrupting this community could have unintended consequences, including colonization by opportunistic organisms or altered inflammatory responses.

The Kent–UCL findings may help explain some observed effects of Centella-derived skin products. Low-level antimicrobial activity from topical madecassic acid could reduce bacterial load on inflamed skin, contributing to perceived benefits in conditions where dysbiosis plays a role. Conversely, repeated exposure to subinhibitory concentrations could select for resistant strains or perturb commensal populations. The net clinical effect will depend on concentration, formulation, frequency of use, and the broader composition of the product.

Manufacturers may need to reassess formulations if further studies confirm significant antimicrobial action at concentrations used in consumer products. For medical-grade topical products intended for wound care or post-procedural use, antimicrobial activity might be desirable. For daily cosmetic use, preserving microbiome balance could argue for lower concentrations or targeted formulations.

The skincare industry and microbiome researchers should collaborate to evaluate whether madecassic acid-containing products alter microbial composition, resistome profiles, or skin immune markers over time. Such studies would inform regulatory guidance and formulation choices.

Real-world precedents: how plant-derived drugs scaled into therapies

History offers instructive parallels. Artemisinin, isolated from Artemisia annua, became the basis for modern antimalarial regimens after decades of refinement. The active endoperoxide pharmacophore required extensive work to produce derivatives with improved pharmacokinetics and to scale production. Paclitaxel’s path from yew bark to a major anticancer drug required innovations in semi-synthetic production and supply chains. Both successes depended on multi-disciplinary collaborations, funding, and regulatory accommodation for new therapeutic classes.

These cases demonstrate several lessons relevant to madecassic acid:

• Natural products often require chemical modification to become clinically useful.
• Supply constraints from wild-harvested plants must be addressed through synthesis or cultivation.
• Interdisciplinary teams—chemists, microbiologists, clinicians, and process engineers—drive progress.
• Public health needs can accelerate development through special regulatory pathways and funding.

Madecassic acid’s path will likely mirror these complexities. The presence of a cosmetic safety record for Centella extracts is helpful but not determinative for systemic use. The specific pharmacology of madecassic acid derivatives will determine whether they can be developed as systemic antimicrobials, topical agents, or adjuvants.

Resistance risk and mitigation strategies

Every new antimicrobial exerts selective pressure on microbial populations. Understanding how and how rapidly bacteria might evolve resistance to cytochrome bd inhibitors is crucial to designing stewardship policies that preserve clinical utility.

Potential resistance mechanisms include:

• Mutations in cytochrome bd that reduce binding affinity for inhibitors while retaining function.
• Upregulation of alternative respiratory complexes compensating for cytochrome bd inhibition.
• Efflux pumps reducing intracellular drug concentrations.
• Metabolic rewiring to reduce dependency on the inhibited pathway.

Laboratory evolution experiments can reveal the ease with which resistance arises, associated fitness costs, and potential cross-resistance with other drugs. If resistance mutations impose a significant fitness cost under natural conditions, resistant strains may struggle to compete once drug pressure is removed—a favorable scenario for clinical stewardship.

Mitigation strategies include:

• Using cytochrome bd inhibitors as adjuncts rather than monotherapies to reduce selective pressure on any single target.
• Limiting use to infections where the drug provides clear benefit, informed by diagnostics that identify pathogens expressing cytochrome bd or conditions where the pathway is essential.
• Monitoring resistance through genomic surveillance and integrating findings into prescribing guidelines.

Public health stakeholders should plan stewardship frameworks contemporaneously with clinical development to preserve long-term efficacy.

Practical next steps: what researchers and funders should prioritize

The Kent–UCL discovery is an early yet compelling step. Priorities for the next phase of work include:

• Expanding spectrum testing across a panel of clinically relevant Gram-negative pathogens (Klebsiella, Pseudomonas, Enterobacter, Acinetobacter) and selected Gram-positives to map activity breadth.
• Determining MICs across strains with diverse resistance mechanisms to assess whether cytochrome bd inhibition bypasses common resistance pathways.
• Assessing cytotoxicity and selectivity indexes in mammalian cell lines to gauge safety margins.
• Performing time-kill and post-antibiotic effect studies to characterize bacteriostatic versus bactericidal dynamics.
• Conducting in vivo efficacy studies in animal infection models that mimic human disease niches where cytochrome bd is important, such as urinary tract infections, biofilm-associated device infections, and intracellular infection models.
• Exploring chemical modifications to improve pharmacokinetics, reduce metabolic liabilities, and optimize oral or parenteral formulations.
• Initiating resistance evolution studies under controlled conditions to identify likely mechanisms and prepare countermeasures.

Funding agencies and industry partners should recognize the strategic value of exploring new antibacterial mechanisms. Public–private partnerships, government incentives, and non-profit initiatives have previously facilitated antibiotic development in areas with high societal need but limited commercial incentives.

Broader public-health context: new targets matter

The AMR crisis demands novel approaches beyond incremental modifications of existing antibiotic classes. Targets not present in humans, such as cytochrome bd, offer an attractive starting point for selective interventions. The discovery of madecassic acid as a cytochrome bd inhibitor demonstrates how natural products remain a fertile source of chemical scaffolds for antimicrobial discovery.

Even if madecassic acid derivatives ultimately serve as adjuvants or topical agents rather than systemic antibiotics, the research enriches the pharmacopeia of approaches to tackle persistent and resistant infections. Every validated target expands the options available to clinicians and public health planners.

Success will depend on integrating discovery science with investment in development, robust preclinical evaluation, and anticipatory stewardship planning. The global health stakes demand sustained effort across these fronts.

Ethical, environmental, and supply considerations

If a madecassic acid–derived therapeutic progresses to widespread use, ethical and environmental considerations will follow. Issues to consider include:

• Sustainable sourcing: Overharvesting wild Centella asiatica populations must be avoided. Scalable semi-synthetic or fully synthetic manufacturing routes can prevent pressure on natural populations and ensure stable supply.
• Access and equity: New antibiotics must be affordable and accessible globally, especially in regions where resistant infections impose heavy burdens. Pricing, licensing, and distribution strategies should reflect public-health priorities.
• Environmental impact: Manufacturing and disposal practices should minimize ecological harm, including release of active compounds into waste streams that could select for environmental resistance.
• Benefit–risk communication: Transparent communication about the intended uses, benefits, and risks will guide responsible adoption among clinicians and consumers.

Thoughtful policies and collaborations can maximize public-health benefits while minimizing negative externalities.

What the discovery does and does not show today

The Kent–UCL study demonstrates a clear biochemical interaction between madecassic acid (and derivatives) and the bacterial cytochrome bd complex, along with in vitro inhibition of resistant E. coli growth. These are foundational discoveries: they validate a novel target and show that a natural product scaffold can inhibit it.

The study does not establish clinical utility. Key unknowns remain: pharmacokinetics, systemic safety, spectrum of activity across clinically relevant pathogens, in vivo efficacy, and how bacteria respond evolutionarily. These gaps define the research agenda going forward.

For consumers of Centella-based skincare products, the findings do not imply immediate cause for alarm. Topical formulations typically contain a mixture of compounds at concentrations chosen for cosmetic endpoints; whether those concentrations exert meaningful antimicrobial effects on skin microbiomes requires direct study.

Final considerations for clinicians, scientists, and policymakers

Clinicians should note an expanding pipeline of innovative antimicrobial strategies that could influence future treatment options. Scientists ought to prioritize mechanistic studies—both to optimize chemical scaffolds and to understand bacterial compensatory responses. Policymakers must sustain funding mechanisms that de-risk antibiotic development and ensure equitable access if new agents reach the clinic.

The madecassic acid story underscores the value of interdisciplinary research that links ethnobotany, computational chemistry, and modern microbiology. It highlights how molecules encountered in daily life—on a cosmetic label or in a traditional remedy—can have unexpected relevance in addressing some of medicine’s toughest challenges.

FAQ

Q: What exactly is madecassic acid? A: Madecassic acid is a triterpenoid compound found in Centella asiatica. It is one of several bioactive constituents derived from the plant and appears in topical cosmetic preparations and traditional herbal uses.

Q: How does madecassic acid affect bacteria? A: Laboratory studies indicate madecassic acid binds to the cytochrome bd complex, a bacterial respiratory enzyme. Binding impairs the complex’s function, disrupting respiration and growth in antibiotic-resistant E. coli strains tested in vitro.

Q: Is cytochrome bd found in humans? A: No. Cytochrome bd is a bacterial terminal oxidase absent from human mitochondria, which makes it an attractive target for selective antibacterial agents.

Q: Does this mean my Centella-containing skincare product can treat infections? A: Not at present. The concentrations and formulations used in cosmetics differ from those required for antimicrobial action, and clinical efficacy has not been demonstrated. Further research is necessary before any therapeutic claims apply to consumer products.

Q: Could bacteria develop resistance to cytochrome bd inhibitors? A: Resistance is always possible. Bacteria might acquire mutations in the target, upregulate alternative respiratory pathways, or use efflux mechanisms. Laboratory evolution studies are needed to assess the ease and clinical likelihood of resistance emergence.

Q: What are the next research steps? A: Researchers will expand testing across bacterial species, optimize chemical derivatives for potency and drug-like properties, evaluate toxicity in mammalian systems, test efficacy in animal infection models, and study resistance mechanisms.

Q: Could madecassic acid derivatives be used with existing antibiotics? A: Potentially. Inhibiting bacterial respiration could sensitize pathogens to existing antibiotics or enhance the immune system’s ability to clear infections. Combination therapy is a promising strategy to explore in preclinical studies.

Q: How long would it take for a madecassic acid–based drug to reach patients? A: Drug development timelines vary widely. From lead optimization through preclinical and clinical trials to regulatory approval typically takes several years, often a decade or more. Timelines can shorten with strong preclinical efficacy, strategic regulatory pathways, and adequate funding.

Q: Are there precedents for plant-derived drugs becoming mainstream therapies? A: Yes. Artemisinin from Artemisia annua became the basis for modern antimalarial treatments, and paclitaxel from the Pacific yew evolved into a major chemotherapy agent. Both required extensive chemical modification and development to achieve clinical use.

Q: Should public policy support this line of research? A: Given the global threat of antimicrobial resistance, funding and policy support for novel targets and scaffolds—including plant-derived leads—represent strategic investments in public health. Incentives, stewardship planning, and international collaboration will be important to convert early discoveries into accessible treatments.